November 27-29 2018
Cambridge, MA, USA

 

Day One
Wednesday, November 28, 2018

Day Two
Thursday, November 29, 2018

08.20
Chair’s Opening Remarks

Evaluating the Challenges & Future of Anti-Fibrotic Therapies

08.30
Mapping the Future of Anti-Fibrotics: Why We’ve Failed & What Needs to be Done for Success

Synopsis

  • Reviewing challenges in demonstrating anti-fibrotic activity to date
  • Assessing function as reflective of changes in fibrosis
  • Outlining considerations for successful anti-fibrotic clinical trials

09.00
Session Details to be Confirmed

  • Sean Muthian Executive Director - External Science Innovations, Allergan

09.30
Speed Networking

Synopsis

This session is the ideal opportunity to get face-to-face time with many of the brightest minds working in the anti-fibrotic drug development and establish meaningful business relationships for the rest of the forum.

10.00
Morning Break

Innovations in Preclinical Modalities to Better Predict Anti-Fibrotic Activity

11.00
Approaches to Identifying Novel Therapeutic Targets for Fibrosis: Lessons Learned & Future Directions

  • Jane Connor Associate Director - MedImmune Respiratory Inflammation & Autoimmune Research , MedImmune

Synopsis

  • Using idiopathic pulmonary fibrosis as an example, experience has provided case histories that demonstrate preclinical validation of a target does not insure clinical efficacy
  • How should we re-think our approaches to identify efficacious new therapies?

11.30
The N-IF Mouse – a New & Unique Fibrosis Model for Preclinical Efficacy Studies

Synopsis

  • Spontaneous development of fibrosis
  • 100% reproducible phenotype
  • Early onset
  • Multi-organ fibrosis

Utilizing Genetics for a Precision Medicine Approach to Fibrosis

12.00
Leveraging Pathways, Subsets & Networks to Better Analyze Clinical Trials: Lessons from Systemic Sclerosis

  • Viktor Martyanov Research Scientist, Geisel School of Medicine at Dartmouth Department of Molecular & Systems Biology

Synopsis

  • Identifying molecular response and relevant pathways modulated by treatment
  • Classifying patients into molecular subsets to characterize disease heterogeneity
  • Applying functional genomic networks to inform potential combination therapies

12.30
Lunch & Networking

Re-Direction Potential of Existing Therapies to Treat Fibrotic Disease

13.30
Outlining Re-Direction Rationale of Existing Anti-Fibrotics to Treat Further Fibrosis Disorders

Synopsis

  • Evaluating the preclinical efficacy of JNK inhibitors in preclinical fibrosis models and Phase 1/2 trial in IPF
  • Understanding rationale of translating efficacy of JNK inhibition from IPF to SSc
  • Assessing experiences with pomalidomide to inform future re-direction decisions

14.00
Targeting Endoglin: Evolving an Oncology Therapy for the Treatment of Fibrosis

Synopsis

  • Analyzing Endoglin as an essential antigenic target expressed on tumor vasculature
    and fibroblasts
  • Detailing the endoglin antibody carotuximab that is currently being studied in a Phase
    3 trial in angiosarcoma
  • Evaluating the potent anti-fibrotic effects of Carotuximab in models of cardiac,
    pulmonary and liver fibrosis

Innovations in Preclinical Modalities to Better Predict Anti-Fibrotic Activity (Continued)

14.30
Improving the Clinical Relevancy of Engineered Tissues for Disease Modelling & Drug Screening in Fibrosis

  • Ruogang Zhao Assistant Professor of Biomedical Engineering, University of Buffalo

Synopsis

  • Demonstrating technological innovation with improved recapitulation of human fibrosis in vitro
  • Utilizing advanced biofabrication technologies such as Organ-on-chip devices to improve the clinical relevancy of engineered tissues
  • Discussing results of Pirfenidone and Nintedanib as a proof of principle

15.00
Afternoon Break & Networking

Disease Case Studies: What is Success Looking Like?

16.00
Achieving Meaningful Clinical Benefit Without Immunosuppression

  • Mark Tepper President & Chief Scientific Officer , Corbus Pharmaceuticals

Synopsis

  • Outlining the mechanism of action of lenabasum – an oral selective CB2 agonist effective in the resolution of inflammation and fibrosis
  • Reviewing the latest results from the Phase 2 study of lenabasum and ongoing openlabel extension study

16.30
Therapeutic Potential of ASK1 Inhibition to Reduce Kidney Injury & Fibrosis

Synopsis

  • Detailing ASK1 as a driver of apoptosis, inflammation and fibrosis in the kidney
  • Highlighting Gilead’s ASK1 inhibitor program for DKD

17.00
Chair’s Closing Remarks